Categories : Obstetrics & Gynaecology Surgeries & ProceduresTags : Leave a comment

Tranexamic Acid Prevents Severe Bleeding in Caesarean Births

On By ModernMedia

New trial adds high quality evidence on benefits of tranexamic acid for high-risk women

Photo by Jonathan Borba on Unsplash

Giving tranexamic acid to women with placenta praevia (when the placenta covers the cervical opening) undergoing caesarean birth leads to a significant yet modest reduction in severe bleeding after delivery with no evidence of an increase in serious adverse events, finds a trial from China published by The BMJ today.

Tranexamic acid is widely used to prevent or reduce heavy bleeding usually after surgery or trauma. It works by inhibiting blood clot breakdown and is recommended for the treatment of severe bleeding after childbirth (postpartum haemorrhage).

But high quality evidence on its prophylactic use to prevent postpartum haemorrhage in high risk women remains scarce.

To address this gap, researchers in China set out to examine the effect of tranexamic acid in women with placenta praevia, a group at high risk of severe bleeding.

The trial included 1694 pregnant women with placenta praevia who were scheduled for caesarean delivery at 24 maternity units across China between July 2023 and March 2025.

Participants received prophylactic oxytocin – standard treatment to reduce blood loss after delivery – and were randomly assigned to receive either intravenous tranexamic acid (845 women) or placebo (849 women) over 10 minutes, starting within five minutes of umbilical cord clamping.

The main outcome measure was postpartum haemorrhage, defined as blood loss of at least 1000 mL or red blood cell transfusion within two days after delivery. Serious adverse events including blood clots, seizures, acute kidney or liver injury, and maternal death, were also recorded.

The results show that prophylactic tranexamic acid reduced the rate of postpartum haemorrhage by 15%, from 35.1% to 29.7% compared with placebo. This means that for every 19 women receiving prophylactic tranexamic acid, one case of postpartum haemorrhage would be prevented.

Rates of serious adverse effects were similar between the two groups.

The researchers acknowledge various limitations including that the findings are specific to women with placenta praevia receiving prophylactic oxytocin and therefore may not apply to other obstetric populations. However, this was a well-designed trial and results were consistent after further analyses, suggesting that the findings are robust.

As such, they conclude: “In a high risk population – specifically, women with placenta praevia undergoing caesarean delivery – prophylactic tranexamic acid leads to a statistically significant but modest reduction in the incidence of postpartum haemorrhage.”

“Future studies in diverse international settings are warranted to validate these results and to identify specific patient subgroups most likely to benefit from prophylactic use of tranexamic acid,” they add.

In a linked editorial, UK researchers point out that this modest reduction in bleeding understates the impact, particularly in women at high risk of harm from bleeding, for whom even modest relative risk reductions translate into worthwhile benefits.

The focus should now shift from whether tranexamic acid reduces bleeding to how it is used to maximise patient benefit, they say, noting that in non-obstetric surgery, tranexamic acid is given before incision, but in caesarean section trials it is delayed until after cord clamping to avoid placental transfer.

They recommend evaluating pre-incision administration for caesarean section, while carefully monitoring maternal and neonatal outcomes.

Source: The BMJ Group

Categories : CancerTags : Leave a comment

New Drug Doubles One-year Survival in Pancreatic Cancer Trial

On By ModernMedia

Phase 2 randomised trial shows 38% reduction in risk of death with the drug when combined with chemotherapy

Kaplan–Meier estimates of OS in the mITT and ITT populations. Nature Medicine, 2026.

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.

In a randomised phase 2 clinical trial, patients who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone. The drug also reduced the risk of death by 38%.

The study is one of only a few successful randomised trials in the last decade to show a survival benefit that would be applicable to a broad population of pancreatic cancer patients, according to the authors.

The study, which was led by Northwestern Medicine, was published in Nature Medicine.

“Pancreatic cancer remains one of the most challenging solid tumours to treat, but these findings provide cautious optimism for patients,” said study lead author Dr Devalingam Mahalingam, professor of medicine in the division of Hematology and Oncology at Northwestern University Feinberg School of Medicine.

“While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging. Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumour types,” added Mahalingam, who also is the associate director of clinical research at Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

How the trial was conducted

The phase 2 trial enrolled 233 patients with metastatic pancreatic cancer across 60 sites in six countries in North America and Europe. Patients were randomly assigned to receive either standard chemotherapy or the same chemotherapy combined with elraglusib.

Those who received elraglusib lived a median of 10.1 months, compared to 7.2 months for those who only received chemotherapy. While that three-month difference may appear modest, it’s partly because the trial included patients whose cancer progressed too quickly to benefit from treatment.

Among patients who benefited from the drug, the impact was pronounced. Twice as many patients who received elraglusib were alive at one year (44% vs 22%) and about 13% of patients in the drug group were alive at two years, compared to none in the chemotherapy group.

Side effects were generally consistent with chemotherapy but slightly more common in the elraglusib group. The most frequent included low white blood cell counts, fatigue and temporary vision changes, which were reversible. Overall, the safety profile of the drug was considered manageable, the authors said in the study.

How elraglusib works

Elraglusib was developed nearly 15 years ago inside Northwestern University labs. It targets a protein known as GSK-3 beta, which plays a role in tumour growth and suppression of the immune system.

Unlike traditional chemotherapy, which aims to kill cancer cells, elraglusib seems to act on the tumour microenvironment – the mix of cancer cells, immune cells and surrounding tissue that can either support or weaken tumours.

Pancreatic tumours are hard to treat in part because of their microenvironment, which is particularly adept at suppressing immune response. In the study, patients who received elraglusib showed increases in cancer-fighting cells within their tumours, offering early evidence that the drug may help re-engage the immune system.

In addition, certain immune-related markers in the blood at the start of the trial were associated with longer survival among patients who received the drug. While these findings are preliminary, they suggest that elraglusib may be particularly effective in certain patients whose immune systems are already primed to respond.

Mahalingam and his colleagues are exploring a larger confirmatory phase 3 trial as funding and partnership allow. They are also interested in studying the drug in combination with other novel therapies to determine if broader clinical benefit can be achieved.

Source: Northwestern University

Categories : Lab Tests and ImagingTags : Leave a comment

Don’t Blame the Iodine For Reactions to Contrast Scans

On By ModernMedia

Patients may often be worried about reactions to the contrast agents used in their scans.

What is a contrast scan?

‘A contrast scan is a medical imaging test, such as a CT scan or MRI,’ says Dr Jean de Villiers, a radiologist and director of SCP Radiology, ‘that uses a special dye called a ‘contrast agent’ to make certain areas of the body easier to see. The contrast helps highlight blood vessels, organs or abnormal tissues, providing clearer and more detailed images. Dr de Villiers talks about the dye, what it is used for and debunks the myth that it is the iodine that causes allergic reactions in some people.

For MRI scans, a different type of contrast is used, which is gadolinium-based and, while allergic reactions are possible, they are extremely rare.

Why is it used?

The contrast agent shows the blood flow through arteries and veins, blockages, bleeding or abnormal growths and detailed organ structure (such as the brain, liver or kidneys).

In short, contrast helps to highlight differences between normal and abnormal tissue, improving diagnosis and treatment planning.

How is the dye administered?

The contrast agent is usually injected into a vein but, in some cases it can be swallowed or given as a rectal enema, depending on the area being examined. It temporarily changes the way radiation or magnetic fields interact with the body’s internal structures.

Is there an iodine allergy risk in a contrast scan?

This is a common concern, but it’s a bit misunderstood.

People often believe they are allergic to iodine because they may have reacted to contrast dye in the past or to shellfish, which contain iodine. However, iodine itself is not an allergen. According to radiologists and allergists, the body doesn’t mount an allergic immune response to iodine as it’s a basic element, essential to human health, particularly for thyroid function.

What causes allergic reactions in contrast scans?

The culprits are usually one of the other compounds, not iodine. Most contrast agents used in CT scans are iodinated contrast agents however, reactions tend to be linked to the chemical structure of the compound, not its iodine content.

Reactions may range from mild (nausea, itching, flushing) to more serious (difficulty breathing or anaphylactoid reactions), which mimic allergies but do not involve the immune system in the same way.

These reactions are typically caused by:

  • Concentration of the contrast agent
  • Molecular structure (ionic vs non-ionic)
  • Patient-specific factors such as history of allergies, asthma or previous reaction to contrast

Advancements in the type of contrast agent used have significantly reduced the rate of reactions in patients.

To confirm: It’s not the iodine, it’s the other compounds attached to the iodine in the dye and the body’s unique response to them. That is why patients are always asked about any previous contrast reactions, asthma or other allergies before being given the contrast injection.

‘Whether you are asked or not,’ says Dr de Villiers, it’s always best to inform the radiology team if you have had any previous allergic contrast reactions.’

Categories : Cardiovascular DiseaseTags : Leave a comment

Digoxin Benefits Heart Failure Patients, Study Shows

On By ModernMedia
Right side heart failure. Credit: Scientific Animations CC4.0

Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session at Heart Failure 2026, [1–3] the annual congress of the Heart Failure Association of the European Society of Cardiology.

Investigations from researchers at University Medical Center Groningen, Netherlands, evaluated the effects of the digitalis glycosides, digoxin and digitoxin, in patients with heart failure (HF) and reduced or mildly reduced left ventricular ejection fraction (HF(m)rEF). 

“Digoxin is the oldest drug in cardiovascular medicine, but there has been uncertainty about its value in HF(m)rEF management,” explained Principal Investigator, Professor Dirk van Veldhuisen. “In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalisations (a secondary endpoint) was observed. Later analyses from DIG showed that lower serum digoxin levels were associated with a favourable effect, while higher digoxin levels worsened prognosis. [4] We conducted the DECISION trial to investigate whether low-dose digoxin has positive effects on cardiovascular outcomes in patients with HF(m)rEF receiving contemporary guideline-recommended treatments.”[1]

The double-blind DECISION trial was conducted at 43 sites in the Netherlands (NCT03783429). Patients with symptomatic mild-to-moderate HF(m)rEF (left ventricular ejection fraction <50%). were randomised to low-dose digoxin or placebo, with a target serum digoxin concentration of 0.5–0.9 ng/mL.  Both patients with sinus rhythm and atrial fibrillation were enrolled. The primary outcome was a composite of total worsening HF events (defined as total hospitalisations or total urgent hospital visits for worsening HF) and cardiovascular mortality. A total of 1001 patients were randomised. The mean age of the participants was 73 years, 28% were women, and 29% had atrial fibrillation.

Low-dose digoxin did not significantly reduce the primary outcome. Over a median follow-up of 36.5 months, 238 primary-outcome events occurred in 131 of 500 patients in the digoxin group, while 291 primary-outcome events occurred in 152 of 501 patients in the placebo group (rate ratio [RR] 0.81; 95% confidence interval [CI] 0.61 to 1.07; p=0.133). Although not statistically significant, the total number of worsening HF events was lower in the digoxin group than in the placebo group (RR 0.76; 95% CI 0.54 to 1.05). Cardiovascular mortality was similar with digoxin and placebo (hazard ratio [HR] 0.93; 95% CI 0.69 to 1.26). Low-dose digoxin was generally well tolerated and safe.

Last year, results were published from the DIGIT-HF trial, which studied another digitalis glycoside, digitoxin, in patients with advanced HF and reduced ejection fraction. [5] Treatment with digitoxin led to a lower risk of death from any cause or hospital admission for worsening HF.

A second presentation at Heart Failure 2026, by Associate Professor Kevin Damman, demonstrated positive overall benefits with digoxin/digitoxin in a meta-analysis of the DECISION, DIGIT-HF and DIG trials. [2] Across 9,013 patients, digitalis glycoside treatment reduced the risk of the primary endpoint of time to cardiovascular death or first worsening HF event compared with placebo (HR 0.85; 95% CI 0.80 to 0.90; p<0.001). This reduction was mostly attributable to the effect on time to the first worsening HF event (HR 0.75; 95% CI 0.69 to 0.81; p<0.001). There was no statistically significant heterogeneity by trial, treatment period or type of digitalis glycoside. In addition, the effect was not attenuated in patients who were already receiving full guideline-directed HF treatment. 

A third presentation, by Professor Peter van der Meer, found that digoxin withdrawal was associated with clinical deterioration. [3] This was a prespecified blinded analysis that followed patients who stopped taking study medication at the end of the DECISION trial, and were subsequently followed for another 6 weeks. Across 587 patients, there were more cardiovascular deaths and HF events in patients after withdrawal of digoxin than after placebo withdrawal (RR 7.37; 95% CI 1.56 to 34.88; p=0.012). 

Summing up the evidence, Professor van Veldhuisen concluded, “In patients with HF(m)rEF, low-dose digitalis glycosides seem to be an effective additional medical treatment option, which are cheap, safe and easy to use. The totality of the evidence supports the role of low-dose digoxin in the contemporary management of HF, with caution warranted when it is stopped.”

References

[1] ‘Low-dose digoxin in heart failure’ presented during the Hottest trials (2) session on 10 May at 13:15 to 14:15 in Room 3, with simultaneous publication in Nature Medicine: https://doi.org/10.1038/s41591-026-04406-6.


[2] ‘DECISION/DIGIT-HF/DIG study level meta analysis’ presented during the Hottest trials (2) session on 10 May at 13:15 to 14:15 in Room 3.


[3] ‘Blinded withdrawal of digoxin or placebo’ presented during the Hottest trials (2) session on 10 May at 13:15 to 14:15 in Room 3. 


[4] Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525−533.


[5] Bavendiek U, Großhennig A, Schwab J, et al. Digitoxin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2025;393:1155–1165.

Source: European Society of Cardiology

Categories : VaccinesTags : Leave a comment

Cipla Secures Vaccine Tender Across Key Immunisation Categories

On By ModernMedia
Photo by Mufid Majnun on Unsplash

Cipla has been awarded a public sector vaccine tender, reaffirming the company’s commitment to strengthening South Africa’s immunisation program through the equitable supply of high‑quality, affordable vaccines.

Cipla submitted bids across several critical paediatric and childhood immunisation categories, including Pneumococcal Conjugate Vaccine (PCV‑10), Rotavirus vaccine, Hepatitis B (Paediatric formulation). These vaccines play a vital role in preventing life‑threatening childhood illnesses and reducing the burden on healthcare systems.

CEO of Cipla Africa, Paul Miller, said: “This tender award marks an important milestone for Cipla as we continue to expand our vaccine footprint in support of national immunisation priorities. We can meaningfully contribute to comprehensive immunisation programmes and long‑term disease prevention efforts.

“Our participation across multiple vaccine categories demonstrates our commitment to addressing critical public health needs and strengthening health outcomes for children and communities.”

Cipla’s vaccine portfolio is underpinned by stringent quality standards and a focus on ensuring continuity of supply reliability. Cipla has a long history of partnering with the Department of Health to support equitable access to quality healthcare, including the supply of antiretrovirals and various vaccines.

Cipla South Africa focus will be ensuring reliability of supply, consistency, and responsible partnership with the public health sector, particularly in communities where access to healthcare remains uneven. CEO of Cipla Africa, Paul Miller, said: “This tender reaffirms our ongoing partnership with the state, as part of Cipla’s mission of ensuring access to quality, affordable healthcare.”

As part of our ethos of “Caring for Life”, we strongly believe in the importance of robust routine immunisation programmes that save lives, reduces inequality and delivery lasting benefits for society as a whole. In public health, progress often comes down to getting the basics right – ensuring vaccines are available, delivered on time, and reach every child who needs them.”

Participation in the Expanded Programme on Immunisation (EPI) aligns with Cipla’s broader mandate to support preventative healthcare and long‑term public health sustainability, said Miller.

Cipla South Africa continues to work closely with healthcare partners and has invested in initiatives to strengthen vaccines knowledge and reduce vaccine hesitancy. For more information about vaccines, visit https://medinformer.co.za/?s=vaccines

Categories : CancerTags : Leave a comment

Is Depression Being Overdiagnosed in Ovarian Cancer Patients?

On By ModernMedia

Study finds that physical symptoms may disproportionately inflate depression scores in patients. 

Photo by Tima Miroshnichenko on Pexels

In addition to causing mental symptoms such as sadness and despair, depression can cause physical sensations including fatigue, headaches, back pain, gastrointestinal issues, and sleep problems.

New research indicates that individuals with ovarian cancer report more of these physical issues at lower levels of depression than people in the general population. Published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may reflect misattribution of cancer-related symptoms to depression in patients with ovarian cancer.

 Research indicates that more than one-quarter of patients with ovarian cancer develop depressive symptoms. Diagnosis is complicated because physical symptoms of depression overlap with those that can arise from cancer-related causes. Investigators examined how physical symptoms of depression are reported relative to other depression symptoms in patients with ovarian cancer at the time of diagnosis and one-year postdiagnosis, comparing the results with those from people without cancer. 

The team found that at diagnosis, patients reported physical symptoms more frequently than people without cancer and at a lower severity of depression (based on cognitive or emotional symptoms). These differences disappeared at the one-year follow-up, when disease processes no longer drove physical sympto “We intend these findings to help guide assessments of depressive symptoms to discriminate between physical symptoms that are related to cancer and cognitive or affective symptoms that may respond to more traditional interventions for depression,” said lead author Rachel Telles, MA, of the University of Iowa. “We hope that more tailored care will improve outcomes for these patients.”

Source: Wiley

Categories : Medical IndustryTags : Leave a comment

From Hospital Wards to Clinic Ownership, SA Nurses Are Becoming Their Own Bosses

On By ModernMedia

“Mpathy Clinics are nurse-led, low-fee primary healthcare facilities with a vision of transitioning from nurse-led to nurse-owned clinics, creating opportunities for nurses to own and operate clinics in their own communities,” said Rhiza Ventures managing director Linda Dunkley.

For decades, nurses were the backbone of South Africa’s healthcare system, present in every ward, every emergency and every recovery room, but rarely in positions of ownership and leadership.

Now, as South Africa marks International Nurses Day on May 12 under the global theme “Empowered Nurses Save Lives”, a growing network of township clinics is transforming nurses from employees into entrepreneurs while helping to ease pressure on overcrowded public healthcare facilities.

Affordable Healthcare and Building Local Economies

In communities where patients often endure long queues at public clinics or cannot afford private healthcare, nurse-led Mpathy Clinics are emerging as an accessible and affordable alternative rooted in empowerment, dignity and community-based care.

The model, driven by NPO Rhiza Babuyile, currently operates 11 clinics in township areas including Umlazi, Naledi, Gugulethu, Tembisa and Diepsloot. Beyond expanding primary healthcare access, the initiative is creating something rarely seen in South Africa’s nursing

“South Africa’s public sector serves roughly 80% of the population, yet clinics routinely face long queues, staff shortages and medicine stockouts. Most primary healthcare services fall within the legal scope of a Professional Nurse and policies like NIMART (Nurse Initiated Management of Antiretroviral Treatment) – leaning on nurses is the only way to scale primary healthcare capacity at a cost the country can afford,” says Rhiza Ventures, Managing Director Linda Dunkley.

For Mpathy, this means helping the Department of Health extend healthcare services into underserved communities while aligning with the Ideal Clinic Realisation programme and supporting the long-term National Health Insurance (NHI) rollout, where accredited primary healthcare facilities serve as the first point of entry.

“Nurse-led PHC clinics like Mpathy are where early detection is possible, response rates are highest, and the cost to both the patient and the public system is lowest,” said Dunkley.

Dunkley added that the clinics were designed to complement, rather than compete with, the public healthcare system. “Mpathy is positioned explicitly as an extension of the Department of Health rather than a parallel system,” she said.

The clinics also contribute to local economic development, not only creating jobs for administrators and community health workers, but   enabling non-nursing entrepreneurs to own clinics and employ qualified nurses, broadening community-based healthcare investment and expanding access to care.

This month alone, a new Mpathy Clinic will open in Orange Farm on 21 May, led by nursepreneur Sister Mbalenhle, and on 19 May an entrepreneur will be inducted into the model in  Zithobeni, Bronkhorstspruit.

‘It’s My Answered Prayer’ — A Nurse Returns Home as Nursepreneur

For professional nurse and nursepreneur Sindiswa Nhlabathi, the model has become deeply personal.  Nhlabathi will this week open the  Mpathy Clinic in Naledi, Orange Farm on 14 May, serving the same community where she was born and raised.

“I was born at Zola, right across from where the Naledi clinic is based. I grew up in a family where no one was formally employed but they were ‘business people’,” she said. Her mother and grandmother sold cakes and goods to support the family. “It wasn’t easy as there was no money for university,” she said.

Before nursing, she worked at a government hospital as a personal assistant manager. Until a friend changed everything. “One day my friend came to me with nursing application forms and persuaded me to apply. I refused telling her that ‘you know I don’t like nursing’ but she insisted. I was accepted and the minute I was exposed to clinical experiments I knew I was born for this.”

After years in public healthcare, including at Zola Clinic, Nhlabathi resigned from her permanent post and was later offered the opportunity to run the Naledi clinic. “When I was studying it never crossed my mind that one day I might own a clinic. It’s my answered prayer. I feel empowered and I don’t even have the words to articulate my heart but one thing I know is that I intend to take this opportunity and make the best out of it,” says Nhlabathi.

At the clinic, children can receive treatment for under R200, while adult consultations with medication cost up to R350.

“Our clinic is private but very affordable,” Nhlabathi adds that “Our community relies on social grants and low incomes, while public clinics remain overwhelmed. Mpathy Clinics are a bridge between private and public healthcare and our priority is to build trusted relationships with the community.”

Visit https://mpathyclinic.co.za/ to find out more.

Categories : Healthcare Politics and RegulationsTags : Leave a comment

NHI Constitutional Court Arguments Hinge on Public Participation

On By ModernMedia
Photo by Wesley Tingey on Unsplash

The Constitutional Court’s hearing over National Health Insurance (NHI) concluded on 7 May. The Board of Healthcare Funders (BHF) and the Western Cape Provincial Government made a combined application challenging the NHI Act on public participation grounds.

The Court is now deliberating; on such complex constitutional matters, it can be weeks to months before a judgment is made. The implementation of NHI remains suspended, following February’s High Court order – President Cyril Ramaphosa and the Minister of Health have formally undertaken not to proclaim or implement any part of the act until the Constitutional Court’s ruling. Other legal challenges are now paused.

What were the arguments?

The hearings focused on one key question: whether Parliament’s process met the constitutional threshold for public participation (primarily under Sections 59 and 72 of the Constitution). Section 59 mandates proactive, reasonable, and meaningful public engagement for the country’s participatory democracy. Formalities alone do not satisfy it – rather, the test is contextual reasonableness aimed at genuine influence. Constitutional Court challenges for national legislation are the main means by which Section 59 is enforced.

The BHF argued that hundreds of thousands of written submissions were effectively ignored; critical information was not provided; and whether, without such information, the test for rational law-making was met.

The Western Cape (led by Premier Alan Winde) focused primarily on deficiencies in the NCOP and provincial stages of the process, arguing that these violated constitutional public-participation requirements and undermined provincial roles. For example, the NCOP process was compressed into only eight weeks, key inputs were ignored, and provincial roles were undermined.

Parliament contended that the process was far more than a “tick-box” exercise, presenting the NHI to the public as a radical, transformative process and that details would only emerge as the project proceeded. [Nevertheless, even a simple calculation would show an NHI budget of R200bn, requiring crippling taxation.] They also argued that accommodations were made, such as extending written comment deadlines. They also argued that changes were made to the Bill, and that engagement does not mean that the legislature agrees, but rather is informed.

Judges raised questions about the integrity and practicality of the public health system in the context of NHI, but the core legal issue remained procedural compliance as opposed to the policy merits.

Is there precedent?

This would not be the first time the Constitutional Court has set aside Acts. In 2006, in a case brought by Doctors for Life, the Choice on Termination of Pregnancy Amendment Act and Traditional Health Practitioners Act were invalidated as Parliament had failed to comply with its section 72(1)(a) constitutional obligation to facilitate public involvement before passing.

Further cases reinforced that inadequate information, rushed timelines, and a lack of consultation over major changes would result in a breach. Parliament, however, argues that Doctors for Life shows that the requirement for participatory democracy has been met.

All parties now await the Court’s decision, which could either uphold the Act, declare it partially or wholly invalid, or remit aspects back to Parliament for correction.

Categories : Metabolic Disorders Respiratory DiseasesTags : Leave a comment

Could an Asthma Medication Also Protect Against MASH?

On By ModernMedia
Credit: Pixabay CC0

Join our podcast as we unpack a study exploring the potential of the asthma medication formoterol as a novel treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe liver condition often linked to diabetes.

The researchers used experiments involving high-fat diet mice and human liver cell cultures to show that this beta 2 adrenergic receptor agonist effectively reduces liver fat accumulation. It does so by stimulating mitochondrial biogenesis and enhancing metabolic efficiency. In addition, a massive retrospective analysis of nearly 60 000 patients revealed that those using long-acting versions of these drugs experienced significantly lower rates of liver complications and reduced mortality.

Categories : HospitalsTags : Leave a comment

Honouring the Nurses that Give Their Heart into Saving Lives

On By ModernMedia

Every day, across South Africa, nurses stand at the frontline of saving lives. They are the steady hands in moments of uncertainty, the compassionate voices during times of fear, and the dedicated professionals who work tirelessly to ensure that patients receive the care they need when it matters most.

As the world commemorates International Nurses Day 2026 under the theme “Our Nurses. Our Future. Empowered Nurses Save Lives,” the South African National Blood Service pays tribute to the remarkable nurses whose compassion, strength, and dedication continue to save lives every single day.

Behind every successful blood donation is a nurse who chose to care.

A nurse who arrives before sunrise. A nurse who comforts anxious donors with a smile. A nurse who stands for hours ensuring every unit of blood collected is safe enough to save a mother, a child, a trauma victim, or a cancer patient. These are the quiet acts of heroism that often go unseen, yet they change lives every day.

At SANBS, nurses are more than healthcare professionals. They are the heartbeat of the organisation’s lifesaving mission. They carry the emotional weight of the work with grace and continue to show up with compassion even on the hardest days.

“Nurses carry the human side of healthcare. They give comfort in moments of fear and hope in moments of uncertainty. At SANBS, we see their sacrifices, their long hours, and the care they pour into every donor and patient. Today we honour them not only for what they do, but for who they are.” said Monique Schreiner, Senior Manager: Donor Relations.

Every drop of blood collected carries the fingerprints of a nurse who cared enough to make sure someone else gets another chance at life.

Whether working at donor centres, mobile clinics, community blood drives, or behind the scenes ensuring quality and safety, SANBS nurses continue to serve with unwavering commitment. Their work demands patience, emotional strength, skill, and empathy. Yet despite the pressure and responsibility they carry, they continue to give so much of themselves to others.

“There is something deeply powerful about the work our nurses do. They stand beside people in vulnerable moments and remind them that humanity still exists through kindness and care. SANBS is proud to walk alongside these incredible professionals who continue to keep the spirit of service alive,” said Monique Schreiner, Senior Manager: Donor Relations.

International Nurses Day is a moment to pause and recognise the people who dedicate their lives to caring for others, often placing the needs of patients and donors before their own. It is a reminder that healthcare is not only built through medicine and technology, but through compassion, patience, and human connection.

This year’s theme speaks directly to the future of healthcare. Empowered nurses strengthen healthcare systems, uplift communities, and save lives. Their wellbeing and support matter because when nurses are valued, entire communities benefit.

For SANBS, celebrating nurses is deeply personal. These are the individuals who hold hands during difficult moments, calm fears with gentle words, and continue to give their all so that others may live.

To every nurse who continues to wear their uniform with pride, compassion, and courage, thank you.

Thank you for the sacrifices no one sees.
Thank you for the comfort you give so freely.
Thank you for keeping hope alive.
And thank you for helping keep the blood of life flowing across South Africa.

Stay connected with SANBS on social media:

  • X (@theSANBS) 
  • Facebook (@SANBS) 
  • Instagram (@thesanbs) 
  • TikTok (@thesanbs)